Leonardo Antonicelli

Leonardo Antonicelli

Auto-generated profile, based on publicly available information

Leonardo Antonicelli

Allergy and Asthma Outpatient Clinic Ancona Italy

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 October 2016 in Multidisciplinary Respiratory Medicine
Verified
Journal Article
Open access
PDF file
GDGennaro D'Amato
Gennaro D'Amato
Carolina VitaleCarolina Vitale
Carolina Vitale
Antonio MolinoAntonio Molino
Antonio Molino
ASAnna Stanziola
Anna Stanziola
Alessandro  Sanduzzi ZamparelliAlessandro Sanduzzi Zamparelli
Alessandro Sanduzzi Zamparelli
GDGennaro D'Amato
Gennaro D'Amato
Despite major advances in the treatment of asthma and the development of several asthma guidelines, people still die of asthma currently. According to WHO estimates, approximately 250,000 people die prematurely each year from asthma. Trends of asthma mortality rates vary very widely across countries, age and ethnic groups. Several risk factors have been associated with asthma mortality, including a history of near-fatal asthma requiring intubation and mechanical ventilation, hospitalization or emergency care visit for asthma in the past year, currently using or having recently stopped using oral corticosteroids (a marker of event severity), not currently using inhaled corticosteroids, a history of psychiatric disease or psychosocial problems, poor adherence with asthma medications and/or poor adherence with (or lack of) a written asthma action plan, food allergy in a patient with asthma. Preventable factors have been identified in the majority of asthma deaths. Inadequate education of patients on recognising risk and the appropriate action needed when asthma control is poor, deficiencies in the accuracy and timing of asthma diagnosis, inadequate classification of severity and treatment, seem to play a part in the majority of asthma deaths. Improvements in management, epitomized by the use of guided self-management systems of care may be the key goals in reducing asthma mortality worldwide

1 May 2021 in Journal of Asthma and Allergy
Verified
Journal Article
Open access
PDF file
Raffaele CampisiRaffaele Campisi
Raffaele Campisi
Claudia CrimiClaudia Crimi
Claudia Crimi
Santi NolascoSanti Nolasco
Santi Nolasco
BBBianca Beghè
Bianca Beghè
LALeonardo Antonicelli
Leonardo Antonicelli
NCNunzio Crimi
Nunzio Crimi
Introduction: Dupilumab is a monoclonal antibody targeting IL-4Rα recently licensed for severe asthma (SA). A Named Patients Program (NPP) was created in Italy before its commercial availability for SA patients with no other available therapeutic options. We aimed to assess the real-world effectiveness of dupilumab in patients with SA and unmet needs. Methods: We performed a multicentre retrospective study, including SA patients admitted to the NPP treated with dupilumab for 12 months. Data on the number of exacerbations, Asthma Control Test (ACT), pre-bronchodilator FEV1%, oral corticosteroids (OCSs) use, FeNO and eosinophils count in peripheral blood were recorded at baseline and after 3, 6, and 12 months. Results: We included 18 SA patients (mean age 53.3± 12.4 years, 66.7% female). Eleven (61.1%) were OCSs dependent. Five patients (27.8%) received previous anti-IgE and/or anti-IL-5 agents. A significant improvement in ACT score (from 15.7± 5.1 to 18.8± 4.8, p=0.023), OCSs intake [10 (5– 25) mg/day to 0 (0– 5) mg/day, p=0.0333] and FeNO [from 25 (20– 80) ppb to 21 (10.9– 55.3) ppb, p=0.0190] was already detected after 3 months of treatment. After 12 months, a statistically significant decrease in the number of exacerbations from 2 (0– 3) to 0 (0– 1) (p< 0.0068) and increase in FEV1% from 73.5± 19.5% to 87.1± 19.2% (p=0.0407) and ACT to a mean value of 22.4± 1.7 (p< 0.0001) and the interruption of OCSs in all the patients (p< 0.0001) was observed. A transient increase in the eosinophil count was observed in five patients (above 1000 cells/μL in 2 cases) after 3 months, without any clinical effect. Conclusion: Dupilumab improved all the explored clinical outcomes after 12 months, and the transient hypereosinophilia did not modify treatment response. These real-world data confirm the results reported in randomized controlled trials and provide an important opportunity to characterize the clinical impact of the treatment in a non-trial setting. Further real-world studies with a larger cohort of patients are needed to confirm these findings.

4 December 2015 in Allergy, Asthma & Clinical Immunology
Verified
Journal Article
Open access
PDF file
LCLucia Cazzoletti
Lucia Cazzoletti
MFMarcello Ferrari
Marcello Ferrari
Mario OlivieriMario Olivieri
Mario Olivieri
GVGiuseppe Verlato
Giuseppe Verlato
LALeonardo Antonicelli
Leonardo Antonicelli
RMRoberto de Marco
Roberto de Marco
Few population-based studies have assessed the prevalence and the risk factors of non-allergic rhinitis (NAR) in comparison to allergic rhinitis (AR). Moreover, epidemiologic data on rhinitis in the elderly subjects and in southern Europe are scarce. This study aimed at estimating the prevalence and at comparing the risk factor distribution of AR and NAR in a general population sample aged 20–84 years in Italy. A questionnaire on respiratory symptoms and risk factors was administered to random samples of the Italian population aged 20–44 (n = 10,494) 45–64 (n = 2167) and 65–84 (n = 1030) in the frame of the Gene Environment Interactions in Respiratory Diseases (GEIRD) study. Current AR and NAR were defined according to the self-reported presence of nasal allergies or of nasal symptoms without a cold or the flu. NAR showed a significant descending pattern in females from 12.0 % (95 % CI 11.1, 13.1) in the 20–44 year age class, to 7.5 % (5.4, 10.3) in the 65–84 year age class (p = 0.0009), and a roughly stable pattern in males, from 10.2 % (9.3, 11.2) to 11.1 % (8.4, 13.9) (p = 0.5261). AR decreased from 26.6 % (25.7, 27.6) in 20–44 years age class to 15.6 % (13.3, 18.0) in the 65–84 years age class (p < 0.0001), without gender difference. Subjects living near industrial plants and ex- and current smokers had a higher risk of NAR. Current smokers had a lower risk and subjects living in a Mediterranean climate a higher risk of AR. AR and NAR are fairly distinct conditions, as they have a different age, gender and risk factor distribution.

14 August 2020 in Allergy
Verified
Journal Article
Open access
PDF file
LALeonardo Antonicelli
Leonardo Antonicelli
CTChiara Tontini
Chiara Tontini
GMGiuseppina Manzotti
Giuseppina Manzotti
LRLuca Ronchi
Luca Ronchi
AVAdriano Vaghi
Adriano Vaghi
MBMaria Beatrice Bilõ
Maria Beatrice Bilõ
Click on the article title to read more.

5 June 2019 in Allergy
Verified
Journal Article
Closed access
PDF file
LALeonardo Antonicelli
Leonardo Antonicelli
CTChiara Tontini
Chiara Tontini
AMAureliano Marchionni
Aureliano Marchionni
BLBeatrice Lucchetti
Beatrice Lucchetti
MGMaria Stella Garritani
Maria Stella Garritani
MBMaria Beatrice Bilõ
Maria Beatrice Bilõ

1 August 2015 in Annals of Allergy, Asthma & Immunology
Verified
Journal Article
Closed access
CTChiara Tontini
Chiara Tontini
LMLucia Marinangeli
Lucia Marinangeli
MCMiriam Cognigni
Miriam Cognigni
MBMaria Beatrice Bilò
Maria Beatrice Bilò
LALeonardo Antonicelli
Leonardo Antonicelli